Allogeneic lymphocyte therapy is the centerpiece of cancer immunotherapy at Oasis of Hope is known as “allogeneic lymphocyte therapy”. The regimen which we employ was developed over a quarter of a century ago by an insightful Japanese physician, Dr. Masaru Kondo, who proved to be far ahead of his time. Dr. Kondo reported that his therapy could achieve significant tumor shrinkage (objective response) in 30% of his patients with disseminated disease.
For an immunotherapy, this is almost unprecedented – a stimulated immune system is known to have the capacity to prevent or slow the formation of new metastases, but immune-mediated regression of pre-existing tumors has been thought to be a very rare occurrence.
Perhaps for this reason, as well as the fact that the mechanistic basis of Kondo’s therapy was then poorly understood, the relatively few cancer scientists who became aware of Dr. Kondo’s work presumably thought that his claims were “too good to be true”, and thus failed to test or implement them.